Short answer
Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Dr. Laura Sepp-Lorenzino appointed director through 2028 annual meeting, adding senior gene-therapy and nucleic-acid expertise.
Lexeo Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Dr. Laura Sepp-Lorenzino appointed director through 2028 annual meeting, adding senior gene-therapy and nucleic-acid expertise
- Science and Technology Committee appointment strengthens oversight of Lexeo’s research and development strategy
- $40,000 annual board cash compensation, plus committee fees
- Initial option grant covering 50,000 shares; 25,000-share annual options begin with the 2027 annual meeting
- Board addition brings experience from Intellia, Vertex, Alnylam, Merck, Taysha, and AskBio
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lexeo Therapeutics, Inc. 8-K filings
Get the next LXEO 8-K as it lands
Follow LXEO for push alerts, or ask the research agent what this filing means.